Start Time: 16:30 January 1, 0000 5:00 PM ET

Vaxart, Inc. (NASDAQ:VXRT)

Q4 2023 Earnings Conference Call

March 14, 2024, 16:30 PM ET

Company Participants

Michael Finney - Interim CEO

Sean Tucker - SVP and Chief Scientific Officer

James Cummings - Chief Medical Officer

Phil Lee - CFO

Edward Berg - SVP and General Counsel

Conference Call Participants

Liang Cheng - Jefferies

Madison Britt Wynne El-Saadi - B. Riley Securities

Operator

Greetings, and welcome to the Vaxart Business Update and Full Year 2023 Financial Results Conference Call. A question-and-answer session will follow management's opening remarks. Individual investors may submit written questions to ir@vaxart.com. As a reminder, this conference is being recorded.

I would now like to turn the webcast over to your host, Ed Berg, Senior Vice President and General Counsel.

Edward Berg

Good afternoon, and welcome to today's call. Joining us from Vaxart are Dr. Michael Finney, Interim Chief Executive Officer; Dr. Sean Tucker, SVP and Chief Scientific Officer; Dr. James Cummings, Chief Medical Officer; and Phil Lee, Chief Financial Officer.

Before we begin, I would like to remind everyone that during this conference call, Vaxart may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations and its product development and regulatory progress, including statements about its ongoing or planned clinical trials.

Actual results could differ materially from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process, and other risks described in the Risk Factors section of Vaxart's most recently filed Annual Report on Form 10-K and also on other periodic reports filed with the SEC. Vaxart undertakes no obligation to update any forward-looking statements after the date of this call.

I'll now turn the call over to Dr. Michael Finney. Mike?

Michael Finney

Thanks, Ed, and thanks to all of you for joining us today. It's a pleasure to be speaking with you at this exciting time in the company's development. As this is my first quarterly call with you, I will begin with a brief introduction of myself and my observations of our company, and then I'll transition the call to the rest of the team to move through our recent accomplishments, clinical programs, upcoming planned milestones, and full year performance.

First, this is my second installment as Vaxart's CEO, having served in a similar capacity from 2009 to 2011. I've been a Vaxart Board member since 2007 and Board Chair since March 2023. Throughout my time with Vaxart, I've seen the company go through many periods of clinical and corporate growth and take on a variety of new challenges. Never have I been more confident in our team and in our trajectory than I am right now.